Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Infrapatellar Nerve Block for Post-operative Knee Arthroscopy Pain Control

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Larry Hsu, Northwestern University
ClinicalTrials.gov Identifier:
NCT01279447
First received: January 17, 2011
Last updated: April 14, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to determine whether infrapatellar branch of the saphenous nerve blocks are effective in decreasing analgesic use, promoting earlier mobility, and improving long term outcome scores after knee arthroscopy.


Condition Intervention Phase
Internal Derangement of Knee
Drug: 0.25% Bupivacaine
Drug: Normal Saline
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Infrapatellar Nerve Block for Post-operative Analgesia for Knee Arthroscopy

Resource links provided by NLM:


Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • Post op Pain Score [ Time Frame: 0 hours ] [ Designated as safety issue: No ]
    immediate postop pain score, Visual Analog Scale. Evaluates pain on scale from 0-10. 0=no pain. 10=maximum pain.


Enrollment: 68
Study Start Date: January 2011
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham Comparator: Placebo
A sham infrapatellar block performed under US guidance with normal saline
Drug: Normal Saline
10cc, single dose, US guided injection
Other Name: Placebo
Experimental: Infrapatellar nerve block
An infrapatellar nerve block performed under US guidance with 0.25% bupivacaine
Drug: 0.25% Bupivacaine
10cc, single dose, US guided injection
Other Name: Nerve block

Detailed Description:

The purpose of this study is to determine whether infrapatellar branch of the saphenous nerve blocks are effective in decreasing analgesic use, promoting earlier mobility, and improving long term outcome scores after knee arthroscopy. Randomized, double-blinded, placebo controlled, study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • planned knee arthroscopy with soft tissue intervention
  • age 18+
  • English speaking

Exclusion Criteria:

  • contraindications to nerve block: eg neuropathy, type 1 diabetes, coagulopathy
  • knee arthroscopy with planned bony intervention
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01279447

Locations
United States, Illinois
Olson Surgical Pavilion
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
Investigators
Principal Investigator: Gordon Nuber, MD Northwestern University
Study Director: Antoun Nader, MD Northwestern University
Study Director: Lawrence Hsu, MD Northwestern University
Study Director: Mark Kendall, MD Northwestern University
  More Information

Publications:
Responsible Party: Larry Hsu, Resident, Northwestern University
ClinicalTrials.gov Identifier: NCT01279447     History of Changes
Other Study ID Numbers: STU00026632
Study First Received: January 17, 2011
Results First Received: December 5, 2013
Last Updated: April 14, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Northwestern University:
infrapatellar nerve
saphenous nerve
knee arthroscopy
nerve block

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Bupivacaine
Anesthetics
Anesthetics, Local
Central Nervous System Agents
Central Nervous System Depressants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014